Viloxazine: Pediatric First Approval.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed, 28 citations in OpenAlex.

1. An Open-Label Extension Study Assessing the Long-Term Safety and Efficacy of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.CNS drugs · 2024
   Trial
2. Photocatalytic Synthesis of Substituted 2-Aryl Morpholines via Diastereoselective Annulation.Journal of the American Chemical Society · 2025
   Article
3. Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms.BMC medicine · 2025
   Review
4. Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis.Therapeutic advances in drug safety · 2024
   Article
5. Report of a Work Group on Sluggish Cognitive Tempo: Key Research Directions and a Consensus Change in Terminology to Cognitive Disengagement Syndrome.Journal of the American Academy of Child and Adolescent Psychiatry · 2023
   Article
6. Pharmacologic Management of Cognitive Disengagement Syndrome (CDS) and Implications for Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment: Emerging Treatments and Recommendations for Future Research.CNS drugs · 2023
   Article
7. Epilepsy and Attention Deficit Hyperactivity Disorder: Connection, Chance, and Challenges.International journal of molecular sciences · 2023
   Review
8. Convergence mechanism of mindfulness intervention in treating attention deficit hyperactivity disorder: Clues from current evidence.World journal of clinical cases · 2022
   Review
9. Viloxazine, a Non-stimulant Norepinephrine Reuptake Inhibitor, for the Treatment of Attention Deficit Hyperactivity Disorder: A 3 Year Update.Health psychology research · 2022
   Article
10. Viloxazine for Attention-Deficit Hyperactivity Disorder: A Systematic Review and Meta-analysis of Randomized Clinical Trials.Journal of central nervous system disease · 2022
    Article
11. Viloxazine for the Treatment of Attention Deficit Hyperactivity Disorder.Health psychology research · 2022
    Article

Corrections and comments

• Erratum issued
  Correction to: Viloxazine: Pediatric First Approval.2023

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as